Miscellaneous

Thank you for your interest in our webinar on the dual role of mast cells, titled "Mast Cells: Can't live with them, can't live without them?". Below, you will find the questions we did not have time to address during the live session with Dr. Marcus Maurer. Q: In cold activated urticaria, is some of it caused by clonotypic IgE whichRead more

Genoskin awarded the Healthtech prize “Transformons la France!” Yesterday, Genoskin was awarded the Healthtech prize at the “Transformons la France!” (Let’s Transform France!) ceremony presented by La Tribune in Toulouse. While the current health crisis calls into question our lifestyles, "Transformons la France!" highlights the talents of tomorrow and gives impact to those who transform society for the better. TheRead more

Genoskin in the News: article on Benzinga Benzinga biotech reporter Shanthi Rexaline recently spoke to GENOSKIN's CEO Pascal Descargues. In the interview, Pascal shared the inspiration behind founding Genoskin: Pascal quickly realized during his postdoctoral fellowship that animal models were not predictive enough. Pascal also had the opportunity to present Genoskin’s technology. He walked Shanthi through the Genoskin workflow: from sourcingRead more

Genoskin featured in a Business Insider article The press is talking about Genoskin! Amid COVID-19 breakout, Genoskin got attention from Business Insider 's reporter Mia Jankowicz.  We recently communicated on our continued efforts during the pandemic and our preferred access program for research on COVID-19. Genoskin's projects and technology caught the eye of Mia Jankowicz. Mia, a journalist specializing inRead more

Genoskin COVID-19 research preferred access program On Friday, March 13th 2020, Genoskin launched a preferred access program for all research teams actively developing therapeutic and vaccine technologies for the COVID-19 pandemic. The World Health Organization (WHO) officially declared on March 11th, the outbreak of COVID-19 a pandemic. The disease caused by SARS-CoV-2 has spread globally. Over 130,000 individuals are affected so

Read more

Genoskin presents its technology in the UK On Thursday, 20th, the Genoskin team will be presenting its technology during a seminar in Slough, UK.  Next Thursday, Business Development Manager, Michael Pastore, and Chief Commercial Officer, Eric Merle will be giving a seminar in Slough, UK. This seminar will be the opportunity to present our ex-vivo skin assay platform and informRead more